We have recently cared for an infant with neonatal hypoglycemia secondary to endogenous organic, hyperinsulinism (blood glucose 22mg/dl; insulin 92uU/ml) that was refractory to diazoxide ...

Rezolute advances therapies for hypoglycemia with RZ358 and RZ402, showing efficacy in trials. Read why RZLT stock is a compelling, albeit cautious, investment.

Rezolute, Inc. announced that the Data Monitoring Committee (DMC) has reviewed the open-label arm of its Phase 3 sunRIZE study for the treatment of congenital hyperinsulinism with ersodetug in ...